Your Medication Isn't Working. Your Genes May Be Why.

CYP2D6 is your liver’s cleanup crew for a massive category of medications. It’s the primary enzyme breaking down roughly one in four of all drugs in the FDA database: SSRIs like paroxetine and fluoxetine, tricyclic antidepressants, beta-blockers for heart rhythm and hypertension, and opioids including codeine. If CYP2D6 doesn’t work well, these medications pile up in your system.

The CYP2D6 gene comes in multiple functional variants. Variants like *4, *10, and *17 produce reduced enzyme activity, or none at all. Roughly 7 to 10 percent of people with European ancestry are poor metabolizers of CYP2D6 substrates. At the other end, gene duplications (having extra copies) turn someone into an ultra-rapid metabolizer. Poor metabolizers can experience toxic drug accumulation at standard doses; ultra-rapid metabolizers often get no therapeutic benefit because the drug clears before it can work.

Imagine taking an antidepressant at a standard dose and feeling foggy, nauseous, or tremulous within days. You report this to your doctor and she lowers the dose. But the dose was already standard. The problem wasn’t the amount. It was that you metabolize the drug slowly and it’s building up. Without knowing your CYP2D6 status, she might keep lowering the dose until it becomes ineffective, leaving you undertreated and frustrated.

CYP2C19 is the enzyme responsible for clearing many antidepressants, as well as proton pump inhibitors (acid reflux medications) and clopidogrel, a blood thinner used after heart attacks and stents. Variants *2 and *3 reduce enzyme function (poor metabolizers); *17 increases it (rapid metabolizers). Depending on ancestry, 2 to 15 percent of people are poor metabolizers for CYP2C19.

Here’s where it gets critical: clopidogrel is a prodrug, meaning it’s inactive until your liver converts it. If you’re a poor CYP2C19 metabolizer, your liver can’t activate the drug, and you get zero antiplatelet protection after a stent placement. You think you’re protected from clotting. You’re not. This is why the FDA included a black-box warning about CYP2C19 poor metabolizers and clopidogrel.

For antidepressants, the problem mirrors CYP2D6. Poor metabolizers accumulate the drug and experience side effects at standard doses. Rapid metabolizers clear it too quickly and don’t respond. You end up chasing the right dose for weeks while your mood disorder remains untreated. Testing tells your doctor whether you need a lower starting dose, a different SSRI you metabolize normally, or a higher dose because you’re a rapid metabolizer.

CYP2C9 controls the breakdown of warfarin, the decades-old blood thinner still used in millions of people with atrial fibrillation and clotting disorders. It also metabolizes NSAIDs like ibuprofen and naproxen, and some statins. Variants *2 and *3 reduce enzyme activity. About 5 to 10 percent of people with European ancestry carry at least one copy of a reduced-function variant.

Warfarin dosing is notoriously narrow. Too little and you don’t prevent clots; too much and you bleed. Doctors adjust doses based on INR (a blood clotting measure) testing, but this is reactive. Poor CYP2C9 metabolizers require significantly lower warfarin doses to stay in the therapeutic window, yet standard dosing protocols don’t account for genetics. Many poor metabolizers end up over-anticoagulated, resulting in bleeding before their first INR check.

You start warfarin at a standard dose, say 5 mg daily. Days later you notice bruising, blood in your urine, or a nosebleed that won’t stop. You’re over-anticoagulated because your liver can’t break down the drug fast enough. If your CYP2C9 status had been known upfront, your doctor would have started you at 2 or 3 mg instead.

VKORC1 encodes the vitamin K epoxide reductase enzyme, which recycles vitamin K in your body. Warfarin works by blocking this enzyme, preventing clot formation. But people with certain VKORC1 variants are naturally more efficient at vitamin K recycling, meaning they need higher warfarin doses to overcome the drug’s effect. Conversely, people with other variants are more sensitive to warfarin’s blocking effect and need lower doses.

The most common variant is the -1639G>A polymorphism. The A allele, carried by roughly 40 percent of people with European ancestry, is associated with higher warfarin sensitivity and lower dose requirements. Carriers of the A allele experience therapeutic anticoagulation at doses 30 to 40 percent lower than the standard population average. If you carry this variant and receive standard dosing, you’re at significant risk for over-anticoagulation and bleeding.

This is particularly important early in warfarin treatment, when INR levels are shifting and dosing is being established. If your VKORC1 status is unknown and you carry a sensitivity variant, you might bleed before your first follow-up appointment. Knowing your genotype allows your doctor to anticipate your needs and start at the right dose from day one.

SLCO1B1 encodes a transporter protein that brings statins (cholesterol-lowering drugs) into liver cells, where they do their job. If this transporter works poorly, statins accumulate in your bloodstream instead of entering the liver, causing systemic toxicity. The most clinically relevant variant is rs4149056 (the *5 allele). Roughly 15 percent of people carry at least one copy of this variant.

Here’s the critical issue: simvastatin is particularly sensitive to SLCO1B1 function. People carrying the *5 variant have significantly reduced statin uptake and are at elevated risk for statin-induced muscle pain and myopathy, even at standard doses. The FDA recommends that people with SLCO1B1 *5/*5 genotypes avoid simvastatin entirely or use a much lower dose. Other statins (pravastatin, rosuvastatin) bypass SLCO1B1 and are safer choices.

You start simvastatin for high cholesterol at 20 mg daily. Weeks later, your legs ache. Your muscles feel weak. You blame the medication, stop it, and assume you can’t take statins. But you might tolerate pravastatin or rosuvastatin just fine. You also might have tolerated simvastatin at a 10 mg dose. Without knowing your SLCO1B1 genotype, you lose access to a medication class that might have helped your cardiovascular health.

TPMT metabolizes thiopurine drugs, including azathioprine and 6-mercaptopurine, used to suppress the immune system in autoimmune disease and some cancers. TPMT variations determine how quickly your body breaks down these drugs. Poor metabolizers accumulate toxic metabolites; rapid metabolizers clear the drug too quickly for it to work.

There are multiple TPMT variants, and prevalence varies by ancestry. Overall, roughly 0.3 percent of people are homozygous poor metabolizers (two copies of non-functional alleles). But another 8 to 10 percent are heterozygous (one functional, one non-functional). Poor TPMT metabolizers who receive standard thiopurine doses face a severe risk of bone marrow suppression, leading to dangerous drops in white blood cells, red blood cells, and platelets. This can happen within weeks and is potentially life-threatening.

If you’re prescribed azathioprine for Crohn’s disease or lupus and your TPMT status is unknown, you might experience severe bone marrow suppression before anyone realizes what’s happening. Your white cell count crashes, leaving you vulnerable to infection. Your hemoglobin drops and you become severely anemic. Had your TPMT genotype been tested before starting the drug, your doctor would have chosen a lower starting dose or a different immunosuppressant entirely.